keyword
MENU ▼
Read by QxMD icon Read
search

rituximab and lymphoma relapse

keyword
https://www.readbyqxmd.com/read/29470615/pre-dosing-with-lilotomab-prior-to-therapy-with-177-lu-lilotomab-satetraxetan-significantly-increases-the-ratio-of-tumor-to-red-marrow-absorbed-dose-in-non-hodgkin-lymphoma-patients
#1
Caroline Stokke, Johan Blakkisrud, Ayca Løndalen, Jostein Dahle, Anne C T Martinsen, Harald Holte, Arne Kolstad
PURPOSE: 177 Lu-lilotomab satetraxetan is a novel anti-CD37 antibody radionuclide conjugate for the treatment of non-Hodgkin lymphoma (NHL). Four arms with different combinations of pre-dosing and pre-treatment have been investigated in a first-in-human phase 1/2a study for relapsed CD37+ indolent NHL. The aim of this work was to determine the tumor and normal tissue absorbed doses for all four arms, and investigate possible variations in the ratios of tumor to organs-at-risk absorbed doses...
February 22, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29469175/presence-of-autoimmune-disease-affects-not-only-risk-but-also-survival-in-patients-with-b-cell-non-hodgkin-lymphoma
#2
Geffen Kleinstern, Mor Averbuch, Rania Abu Seir, Riki Perlman, Dina Ben Yehuda, Ora Paltiel
Although autoimmune diseases (AIDs) are known to predispose to non-Hodgkin lymphoma (NHL), their association with NHL prognosis has rarely been investigated. We examined associations between autoimmunity and B-cell NHL onset by comparing AID history (determined by self-report and medication review and supplemented by chart review where possible) among 435 adult B-NHL patients in Hadassah-Hebrew University Medical Center, diagnosed 2009-2014, and 414 age-and-sex frequency-matched controls. We examined AIDs as a whole, B- and T-cell-mediated AIDs, and autoimmune thyroid diseases...
February 22, 2018: Hematological Oncology
https://www.readbyqxmd.com/read/29463854/autologous-stem-cell-transplantation-for-primary-mediastinal-b-cell-lymphoma-long-term-outcome-and-role-of-post-transplant-radiotherapy-a-report-of-the-european-society-for-blood-and-marrow-transplantation
#3
Irit Avivi, Ariane Boumendil, Hervé Finel, Arnon Nagler, Aïda Botelho de Sousa, Josep Maria Ribera Santasusana, Elizabeth Vandenberghe, Boris Afanasyev, Dominique Bordessoule, José Maria Moraleda, Eulogio Conde Garcia, David Pohlreich, Gonzalo Gutiérrez Garcia, Kirsty Thomson, Reuven Or, Dietrich Beelen, Eliana Zuffa, Sebastian Giebel, Christian Berthou, Gilles Salles, Angela Melpignano, Silvia Montoto, Peter Dreger
The purpose of this retrospective registry study was to investigate the outcome of autoSCT for primary mediastinal B-cell lymphoma (PMBCL) in the rituximab era, including the effects of eventual post-transplant radiotherapy (RT) consolidation. Patients with PMBCL aged between 18 and 70 years who were treated with a first autoSCT between 2000 and 2012 and registered with the EBMT were eligible. Eighty-six patients with confirmed PMBCL and the full data set required for this analysis were evaluable. Sixteen patients underwent autoSCT in remission after first-line therapy (CR/PR1), 44 patients were transplanted with chemosensitive relapsed or primary refractory disease (CR/PR >1), and 24 patients were chemorefractory at the time of autoSCT...
February 20, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29453281/the-pi3k%C3%AE-selective-inhibitor-idelalisib-minimally-interferes-with-immune-effector-function-mediated-by-rituximab-or-obinutuzumab-and-significantly-augments-b-cell-depletion-in-vivo
#4
Adam Palazzo, Sylvia Herter, Laura Grosmaire, Randy Jones, Christian R Frey, Florian Limani, Marina Bacac, Pablo Umana, Robert J Oldham, Michael J E Marshall, Kerry L Cox, Anna H Turaj, Mark S Cragg, Christian Klein, Matthew J Carter, Stacey Tannheimer
Idelalisib is a highly selective oral inhibitor of PI3Kδ indicated for the treatment of patients with relapsed chronic lymphocytic leukemia in combination with rituximab. Despite additive clinical effects, previous studies have paradoxically demonstrated that targeted therapies potentially negatively affect anti-CD20 mAb effector mechanisms. To address these potential effects, we investigated the impact of PI3Kδ inhibition by idelalisib on the effector mechanisms of rituximab and obinutuzumab. At clinically relevant concentrations, idelalisib minimally influenced rituximab- and obinutuzumab-mediated Ab-dependent cellular cytotoxicity and phagocytosis on human lymphoma cell lines, while maintaining the superiority of obinutuzumab-mediated Ab-dependent cellular cytotoxicity...
February 16, 2018: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/29452664/the-role-of-stem-cell-transplantation-in-follicular-lymphoma
#5
REVIEW
Georg Hess
With the introduction of novel treatments paradigms to if or when to use transplantation strategies for patients with follicular lymphoma have changed substantially. Autologous transplantation has been intensively evaluated as consolidation after first induction treatment with positive effects, however the introduction of Rituximab led to comparable improvements and HDT has been moved to relapse treatment. In this indication HDT was frequently use already at first relapse, but now is dominantly used in patients with a highrisk profile, e...
March 2018: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29450588/response-rates-and-recurrence-patterns-after-low-dose-radiotherapy-with-4-gy-in-patients-with-low-grade-lymphomas
#6
Laila König, Juliane Hörner-Rieber, Denise Bernhardt, Adriane Hommertgen, Stefan Rieken, Jürgen Debus, Klaus Herfarth
PURPOSE: Retrospective study of effectiveness, toxicity, and relapse patterns after low-dose radiotherapy (LDRT) in patients with low-grade lymphomas. METHODS: 47 patients (median age 64 years) with 50 lesions were treated with LDRT (2 × 2 Gy). In 60%, LDRT was the primary and curative treatment, in 40% offered as second-line therapy in recurrent disease. Histology included follicular (57%) and marginal zone lymphomas (43%). Patients were followed-up regularly clinically (skin) and with CT or MRI scans...
February 15, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29444231/phase-iia-study-of-the-cd19-antibody-mor208-in-patients-with-relapsed-or-refractory-b-cell-non-hodgkin-s-lymphoma
#7
W Jurczak, P L Zinzani, G Gaidano, A Goy, M Provencio, Z Nagy, T Robak, K Maddocks, C Buske, S Ambarkhane, M Winderlich, M Dirnberger-Hertweck, R Korolkiewicz, K A Blum
Background: This two-stage, phase IIa study (ClinicalTrials.gov: NCT01685008) investigated the antitumor activity and safety of MOR208, an Fc-engineered, humanized, CD19 antibody, in patients with relapsed or refractory (R-R) B-cell non-Hodgkin's lymphoma (NHL). CD19 is broadly expressed across the B-lymphocyte lineage, including in B-cell malignancies, but not by hematological stem cells. Patients and methods: Patients aged ≥18 years, with R-R NHL progressing after ≥1 prior rituximab containing regimen were enrolled into subtype-specific cohorts: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), other indolent (i)NHL and mantle cell lymphoma (MCL)...
February 9, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29411260/a-case-of-conjunctival-malt-lymphoma-successfully-treated-with-solely-extended-rituximab-therapy
#8
Hande Celiker, Ebru Toker, Isik Kaygusuz Atagunduz
PURPOSE: Primary ocular adnexal lymphomas are cured by radiotherapy; however, complications are frequent and relapses may occur. In this case, we aimed to report the efficacy and safety of extended systemic rituximab (anti-CD 20 monoclonal antibody) therapy of conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma. METHODS: In the standard regimen, rituximab is used as four consecutive weekly infusions of 375 mg/m2 in patients with low-grade lymphomas. We treated a patient who had bilateral conjunctival MALT lymphoma with rituximab 375 mg/m2 intravenously once weekly for 10 weeks as a first-line therapy...
February 6, 2018: International Ophthalmology
https://www.readbyqxmd.com/read/29396091/ibrutinib-lenalidomide-and-rituximab-in-relapsed-or-refractory-mantle-cell-lymphoma-philemon-a-multicentre-open-label-single-arm-phase-2-trial
#9
Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Helle Toldbod, Lone Bredo Pedersen, Carsten Utoft Niemann, Christina Dahl, Hanne Kuitunen, Christian H Geisler, Kirsten Grønbæk, Arne Kolstad
BACKGROUND: Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs would improve efficacy compared with previously published data on either regimen alone. METHODS: In this multicentre, open-label, single-arm, phase 2 trial, we enrolled patients aged 18 years or older with relapsed or refractory mantle cell lymphoma who had previously been treated with at least one rituximab-containing regimen, an Eastern Cooperative Oncology Group performance status score of 0-3, and at least one site of measurable disease, and who met criteria for several laboratory-assessed parameters...
January 29, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29386196/a-phase-i-study-of-ibrutinib-in-combination-with-r-ice-in-patients-with-relapsed-or-primary-refractory-dlbcl
#10
Craig S Sauter, Matthew J Matasar, Heiko Schoder, Sean M Devlin, Pamela Drullinsky, John Gerecitano, Anita Kumar, Ariela Noy, Maria L Palomba, Carol S Portlock, David J Straus, Andrew D Zelenetz, Susan J McCall, Shoshana T Miller, Amanda I Courtien, Anas Younes, Craig H Moskowitz
In the post-rituximab era, approximately half the patients with relapsed or refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) fail to achieve a chemosensitive response to standard salvage therapy, and are thus ineligible to proceed to autologous stem cell transplantation (ASCT) with curative intent. The Bruton's tyrosine kinase inhibitor ibrutinib demonstrates single-agent activity in rel/ref DLBCL, particularly of non-germinal center (non-GC) cell-of-origin (COO). We conducted a single center phase I study evaluating dose escalated ibrutinib, in a 3 by 3 design, in combination with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) in physiologically transplant-eligible rel/ref DLBCL patients...
January 31, 2018: Blood
https://www.readbyqxmd.com/read/29348832/clinical-and-histological-features-of-primary-testicular-diffuse-large-b-cell-lymphoma-a-single-center-experience-in-china
#11
De Zhou, Changqian Bao, Xiujin Ye, Lixia Zhu, Jingjing Zhu, Li Li, Mingyu Zhu, Xiudi Yang, Yanlong Zheng, Xianbo Huang, Mixue Xie, Wanzhuo Xie
Primary testicular lymphoma (PTL) is a rare and aggressive form of extranodal lymphoma. Approximately 80-98% of PTLs are diffuse large B-cell lymphoma (PT-DLBCL). The prognosis of DLBCL patients has improved with the addition of rituximab to systemic chemotherapy, but outcomes of PT-DLBCL remain poor. This may be explained by the high rate of relapse in the central nervous system (CNS) and contralateral testis. We analyzed 1,132 newly diagnosed DLBCL patients (37 with PT-DLBCL) who were treated at our hospital between January 2009 and December 2014...
December 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29340761/long-term-efficacy-and-toxicity-of-rituximab-plus-fludarabine-and-mitoxantrone-r-fm-for-gastric-marginal-zone-lymphoma-a-single-center-experience-and-literature-review
#12
Emanuele Cencini, Alberto Fabbri, Francesco Lauria, Monica Bocchia
There is no consensus about the best treatment option for patients with HP-negative gastric MALT lymphomas or persistent disease after HP eradication.We have investigated fludarabine and mitoxantrone with rituximab (R-FM) as first-line treatment. A cohort of 13 patients was analyzed. Induction treatment consisted of fludarabine (25 mg/m2 i.v. on days 2 to 4), mitoxantrone (10 mg/m2 i.v. on day 2), and rituximab (375 mg/m2 i.v. on day 1), for up to six cycles every 28 days. All patients achieved a complete remission, a median of four cycles was given...
January 16, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29337112/molecular-heterogeneity-in-diffuse-large-b-cell-lymphoma-and-its-implications-in-clinical-diagnosis-and-treatment
#13
REVIEW
Lingchuan Guo, Pei Lin, Hui Xiong, Shichun Tu, Gang Chen
Over half of patients with diffuse large B-cell lymphoma (DLBCL) can be cured by standard R-CHOP treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). However, the remaining patients are refractory and ultimately succumb to progressive or relapsed disease. During the past decade, there has been significant progress in the understanding of molecular mechanisms in DLBCL, largely owing to collaborative efforts in large-scale gene expression profiling and deep sequencing, which have identified genetic alterations critical in lymphomagenesis through activation of key signaling transduction pathways in DLBCL...
January 11, 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29320913/a-phase-2-study-of-rituximab-cyclophosphamide-bortezomib-and-dexamethasone-r-cybord-in-relapsed-low-grade-and-mantle-cell-lymphoma
#14
Mohamad Bassam Sonbol, Talal Hilal, Amylou C Dueck, Allison C Rosenthal, Christopher R Conley, Heidi E Kosiorek, Brenda F Ginos, Katherine M Gano, Craig S Nichols, Jose F Leis, Patrick B Johnston, Thomas M Habermann, Donald W Northfelt, Peter Leif Bergsagel, David J Inwards, Thomas E Witzig, Stephen M Ansell, Craig B Reeder
In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexamethasone, and bortezomib 1.3 mg/m2 IV in a 28-day cycle. Twenty one patients were enrolled on the study. Median age was 69 years (range 51-80) and 17 (81%) patients had two or more prior treatments. Histologies included FL (n = 8), MCL (n = 8), and LPL/WM (n = 5)...
January 10, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29318369/the-incidence-of-biopsy-proven-transformation-in-follicular-lymphoma-in-the-rituximab-era-a-retrospective-analysis-from-the-czech-lymphoma-study-group-clsg-database
#15
Andrea Janikova, Zbynek Bortlicek, Vit Campr, Natasa Kopalova, Katerina Benesova, Michaela Hamouzova, David Belada, Vit Prochazka, Robert Pytlik, Samuel Vokurka, Jan Pirnos, Juraj Duras, Heidi Mocikova, Jiri Mayer, Marek Trneny
The aim of this study is to assess the incidence, risk factors, and outcome of biopsy-proven transformation in follicular lymphoma (FL) patients in the rituximab era. Transformation was analyzed in 1233 patients with initially diagnosed FL grades 1-3A, identified between 2002 and 2012 in the prospectively maintained Czech Lymphoma Study Group database. Only patients with histologically proven transformation (HT) were included. HT occurred in 58 cases at a median of 3.0 years from the initial FL diagnosis; the HT rate was 4% at 5 years...
January 9, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29317554/bendamustine-plus-rituximab-versus-r-chop-as-first-line-treatment-for-patients-with-follicular-lymphoma-grade-3a-evidence-from-a-multicenter-retrospective-study
#16
Patrizia Mondello, Normann Steiner, Wolfgang Willenbacher, Claudio Cerchione, Davide Nappi, Endri Mauro, Simone Ferrero, Salvatore Cuzzocrea, Michael Mian
BACKGROUND: Rituximab plus bendamustine (R-B) has been demonstrated to improve outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) in follicular lymphoma (FL). Nevertheless, in clinical practice, many centers still prefer R-CHOP to R-B in patients with FL grade 3A (FL3A). Therefore, we retrospectively assessed patients with FL3A treated with either R-CHOP or R-B in five European cancer centers and compared their outcomes. MATERIALS AND METHODS: We retrospectively assessed 132 patients affected by FL grade 3A treated with either R-B or R-CHOP in the first line and evaluated outcome and toxicity according to the type of treatment...
January 9, 2018: Oncologist
https://www.readbyqxmd.com/read/29315142/enteroviral-encephalitis-in-a-child-with-cns-relapse-of-burkitt-leukemia-treated-with-rituximab
#17
Najma Shaheen, Francis Mussai
A boy with central nervous system relapse of Burkitt leukemia developed fever and neurological symptoms and cognitive impairment. He had received multi-drug chemotherapy including rituximab. Enterovirus (EV) was detected in cerebrospinal fluid by polymerase chain reaction, and magnetic resonance imaging findings were consistent with viral infection. The patient was treated with intravenous immunoglobulin and within 1 month cleared his EV. Rituximab can cause a profound B-cell deficiency predisposing patients to infections including EV encephalitis...
January 8, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29306309/-intravitreal-rituximab-for-the-treatment-of-intraocular-relapse-of-non-hodgkin-s-lymphoma
#18
Eva Fernández Cañabate, Sonia Fernández-Cañabate
CLINICAL CASE: A 58-year-old woman with intraocular relapse of a diffuse large B cell lymphoma. Weekly intravitreal rituximab (1 mg/0.1 ml) for 4 weeks were  administered. 12 months after the last intravitreal rituximab dose, signs and  symptoms of lymphomas or adverse reactions associated with intravitreal Rituximab  administration were not observed. DISCUSSION: Intravitreal rituximab is an effective and safe treatment of intravitreal  lymphoma, by inducing complete remission; it could be a good alternative to other  therapeutic options with greater number of serious complications...
January 1, 2018: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/29301121/association-of-soluble-interleukin-2-receptor-and-c-reactive-protein-with-the-efficacy-of-bendamustine-salvage-treatment-for-indolent-lymphomas-and-mantle-cell-lymphoma
#19
Yukiko Kawaguchi, Tsuyoshi Nakamaki, Maasa Abe, Yuta Baba, So Murai, Megumi Watanuki, Nana Arai, Shun Fujiwara, Nobuyuki Kabasawa, Hiroyuki Tsukamoto, Yui Uto, Hirotsugu Ariizumi, Kouji Yanagisawa, Norimichi Hattori, Hiroshi Harada, Bungo Saito
Bendamustine has demonstrated favourable efficacy in relapsed or refractory indolent lymphoma and mantle cell lymphoma. We retrospectively evaluated the pre-treatment clinical and laboratory factors and their correlation with the clinical outcome of these lymphomas. We analysed 53 patients who had been treated with bendamustine alone (n = 6) or rituximab plus bendamustine (n = 47). The overall response rate was 81.1%, with a complete response (CR) rate of 39.6%. The CR rate was significantly low in patients who had elevated levels of soluble interleukin-2 receptor (p = 0...
January 5, 2018: Acta Haematologica
https://www.readbyqxmd.com/read/29295653/improvement-of-fatigue-physical-functioning-and-well-being-among-patients-with-severe-impairment-at-baseline-receiving-ibrutinib-in-combination-with-bendamustine-and-rituximab-for-relapsed-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-in-the-helios
#20
Paula Cramer, Graeme Fraser, Rodrigo Santucci-Silva, Sebastian Grosicki, Marie-Sarah Dilhuydy, Ann Janssens, Javier Loscertales, Simon Rule, Andre Goy, Shana Traina, Eric K H Chan, Joris Diels, Nishan Sengupta, Michelle Mahler, Mariya Salman, Angela Howes, Asher Chanan-Khan
Health-related quality of life (HRQoL) is an important endpoint, especially in clinical trials for malignancies with a long course of disease, such as chronic lymphocytic leukemia (CLL). Patient-reported outcomes were examined in the randomized, double-blind, placebo-controlled HELIOS study to assess the impact of treatment with the Bruton's tyrosine kinase inhibitor ibrutinib, added to bendamustine plus rituximab (BR) background therapy. Measures included FACIT-Fatigue, EORTC QLQ-C30, QLQ-CLL16, and EQ-5D-5L...
January 3, 2018: Leukemia & Lymphoma
keyword
keyword
114416
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"